Lomedeucitinib vs zasocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Lomedeucitinib

Developed by Beeline Medicines under a licence from Bristol-Myers Squibb

Phase 2 in Psoriasissmall molecule
Partial signal

NCT05730725 · Phase 2 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.

Reported efficacy

Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)

Result source: NCT05730725

zasocitinib

Developed by Takeda Pharmaceutical Company

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06108544 · Phase 3 · completed

This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07752108 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)

Result source: NCT06973291

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLomedeucitinibzasocitinib
PASI 7563% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
67.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043
PASI 9040.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
46.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
PASI 1003.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
32.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
sPGA 0/155.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
51.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043
DLQI, change—Not reported-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839

PASI 75

Lomedeucitinib
63% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
zasocitinib
67.3% vs 5.8%+61.5 vs placebo30 mg · wk 12 · n 52NCT04999839
4 other results
  • 67.9% vs 5.8% 15 mg · wk 12 · n 53 · Phase 2 · primary NCT04999839
  • 44.2% vs 5.8% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT04999839
  • 18% vs 5.8% 2 mg · wk 12 · n 50 · Phase 2 · primary NCT04999839
  • 75.7% vs 12.1% wk 16 · Phase 3 · primary NCT06088043

PASI 90

Lomedeucitinib
40.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
zasocitinib
46.2% vs 0%+46.2 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 45.3% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 21.2% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 8% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

PASI 100

Lomedeucitinib
3.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
zasocitinib
32.7% vs 0%+32.7 vs placebo30 mg · wk 12 · n 52NCT04999839
3 other results
  • 15.1% vs 0% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 9.6% vs 0% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 2% vs 0% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839

sPGA 0/1

Lomedeucitinib
55.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
zasocitinib
51.9% vs 3.8%+48.1 vs placebo30 mg · wk 12 · n 52NCT04999839
5 other results
  • 49.1% vs 3.8% 15 mg · wk 12 · n 53 · Phase 2 · secondary NCT04999839
  • 26.9% vs 3.8% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT04999839
  • 10% vs 3.8% 2 mg · wk 12 · n 50 · Phase 2 · secondary NCT04999839
  • 69.2% vs 12.6% wk 16 · Phase 3 · primary NCT06108544
  • 71.4% vs 10.7% wk 16 · Phase 3 · primary NCT06088043

DLQI, change

Lomedeucitinib
—Not reported
zasocitinib
-8.9 vs -4.9−4 vs placebo30 mg · wk 12 · n 47NCT04999839
3 other results
  • -8.5 vs -4.9 15 mg · wk 12 · n 46 · Phase 2 · secondary NCT04999839
  • -7.9 vs -4.9 5 mg · wk 12 · n 47 · Phase 2 · secondary NCT04999839
  • -5.3 vs -4.9 2 mg · wk 12 · n 43 · Phase 2 · secondary NCT04999839
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lomedeucitinib: 3 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLomedeucitinibzasocitinib
Dropout rate
7.4%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
3.7%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
9.6%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
13.2%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
13.5%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
16%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
—BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
—BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
1.9%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
1.9%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
2%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Serious AEs
0%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
0%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0%30 mga
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
1.9%15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
acne 14.8% (placebo 0%)
covid-19 11.1% (placebo 0%)
dermatitis acneiform 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
aphthous ulcer 11.1% (placebo 0%)
folliculitis 11.1% (placebo 0%)
upper respiratory tract infection 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
diarrhoea 7.4% (placebo 0%)
headache 7.4% (placebo 0%)
influenza 7.4% (placebo 3.6%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30 mga
covid-19 13.5% (placebo 1.9%)
blood creatine phosphokinase increased 5.8% (placebo 3.8%)
dermatitis acneiform 5.8% (placebo 0%)
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
15 mg
covid-19 11.3% (placebo 1.9%)
acne 5.7% (placebo 0%)
blood creatine phosphokinase increased 5.7% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
5 mg
covid-19 7.7% (placebo 1.9%)
lymphocyte count decreased 5.8% (placebo 0%)
blood creatine phosphokinase increased 3.8% (placebo 3.8%)
NCT04999839 · Phase 2 · registry result, not featured evidence
2 mg
covid-19 12% (placebo 1.9%)
alanine aminotransferase increased 6% (placebo 0%)
diarrhoea 6% (placebo 1.9%)
NCT04999839 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lomedeucitinib

PASI 50 81.5% (n=27) vs 17.9% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
24% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
65.4% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
88.5% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=26) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
34.6% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
85.2% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
73.9% (n=23) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
14.8% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48.1% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
84% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
81.8% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI -3.36 vs -0.5 placebo score @ 1wk
absolute change · score
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 14 more results
-6.27 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.05 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.06 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.44 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.95 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.13 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.63 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.66 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.39 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.85 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.16 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-8.53 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.34 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.55 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

zasocitinib

DLQI -8.9 vs -4.9 placebo score @ 12wk30 mg
absolute change · score
NCT04999839 · Phase 2 · registry result, not featured evidence
show 3 more results
-8.5 vs -4.9 placebo score @ 12wk15 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
-7.9 vs -4.9 placebo score @ 12wk5 mg
NCT04999839 · Phase 2 · registry result, not featured evidence
-5.3 vs -4.9 placebo score @ 12wk2 mg
NCT04999839 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lomedeucitinib's landscape · zasocitinib's landscape